Acute Myeloid Leukemia (AML) is marked by the rapid proliferation of abnormal hematopoietic stem cells, leading to a high relapse rate despite initial treatment success. Traditional treatment has involved anthracyclines and cytosine arabinoside (AraC), known collectively as conventional chemotherapy. More recently, targeted therapies like the combination of Venetoclax  with Hypomethylating agents (VH) have shown promise. Despite these advancements, the heterogeneity in patient response necessitates tailored therapeutic strategies. To this end, a new study published in Leukemia and conducted by Dr. Eduardo Sabino de Camargo Magalhães, Dr. Stefan Edward Hubner, Dr. Brandon Douglas Brown, Dr. Yihua Qiu & led by Professor Steven Mitchell Kornblau at the University of Texas MD Anderson Cancer Center, the researchers ran a proteomic-based approach using Reverse-phase Protein Arrays (RPPA) for enhancing therapy selection between VH and conventional chemotherapy in AML patients. They aimed to refine treatment selection between VH and conventional chemotherapy by employing a proteomic profiling strategy to identify predictive protein signatures. The analysis of 810 patients revealed distinct protein profiles that could potentially guide treatment decisions, increasing overall survival rates and the possibility of achieving remission.

First, the researchers collected blood and bone marrow samples from newly diagnosed adult AML patients at the University of Texas MD Anderson Cancer Center.  Samples were processed shortly after collection, using Ficoll gradient centrifugation to separate mononuclear cells, followed by Magnetic Activated Cell Sorting (MACS) to deplete T and B cells. Afterward, samples were lysed to extract proteins, which were then denatured and arrayed on nitrocellulose-coated slides in a series of five 2-fold serial dilutions. Slides were probed with 411 validated antibodies (including both total and phosphorylated proteins) and detected using secondary antibodies linked to an infrared dye. The stained slides were scanned to quantify protein levels, with data normalized against protein levels in normal bone marrow-derived CD34+ cells.  The team employed machine learning algorithms (primarily random forests) to analyze the protein expression data. The aim was to develop a classifier capable of predicting which treatment modality (VH or conventional chemotherapy) would be most effective for each patient. Using expression data, they identified 109 proteins with significant prognostic value. Further analysis refined this to 14 key proteins that effectively discriminated between optimal treatment regimens. The model’s predictions were validated against clinical outcomes, focusing on overall survival and treatment efficacy.

The team successfully identified 109 proteins that had prognostic value in AML. These proteins were used to categorize patients into five distinct expression profiles that correlate with different clinical outcomes. A subset of 14 out of the 109 proteins was found to be particularly effective in predicting the best treatment approach. This classifier can be used to guide the choice between VH and conventional chemotherapy, aiming to maximize patient response and survival. Implementing the proteomic classifier was projected to lead to a change in therapy for about 30% of the patients. This adjustment was estimated to increase the 5-year overall survival rate by 43%, translating to approximately 2600 additional cures annually in the United States. Beyond the immediate application in AML, this approach has potential implications for other types of cancer where treatment optimization remains a challenge. The method’s scalability and the detailed molecular insights it provides could facilitate wider adoption in personalized medicine. Importantly, the study also identified a group of patients who did not benefit from either VH or conventional chemotherapy, suggesting the need for alternative therapeutic strategies for this subgroup.

The significance of the study lies in its potential to revolutionize the treatment of AML through the use of proteomic profiling and machine learning algorithms.  First, the study proposes a method to tailor AML treatment plans based on individual protein expression profiles, moving away from a one-size-fits-all approach and towards more personalized medicine. This has the potential to significantly increase the effectiveness of treatments by matching patients with the therapies most likely to benefit them. Secondly, by identifying specific protein signatures that correlate with better responses to either Venetoclax combined with Hypomethylating agents or conventional chemotherapy, the study suggests that it could be possible to increase overall survival rates and complete remission durations for AML patients. This would represent a major advance in a disease area where outcomes have historically been poor. Thirdly, by more accurately predicting which patients will benefit from which treatment regimens, unnecessary exposure to potentially ineffective and toxic treatments can be minimized. This not only improves quality of life but also reduces healthcare costs associated with ineffective treatment. Moreover, the study enhances understanding of the molecular underpinnings of AML through detailed proteomic analysis. Such insights are invaluable for the development of new therapeutic targets and improving existing treatments. Furthermore, using RPPA technology combined with machine learning offers a scalable method for analyzing protein expression in other cancers and diseases, suggesting that this approach could have broad applications beyond AML. The study estimates that implementing its findings could lead to around 2600 more cures annually in the United States alone, underlining its significant potential impact on public health.

Overall, the integration of RPPA-based proteomic profiling into clinical practice could significantly impact the management of AML by providing a more nuanced understanding of disease biology and patient-specific therapeutic responses. The new method reported by Professor Steven Mitchell Kornblau and his team holds promise for improving patient outcomes through tailored treatment strategies, thus marking a significant advance in the personalized treatment of AML.

The autonomic nervous system (ANS) plays a major role in maintaining the physiological integrity and health of the eyes.  The ANS regulates the dilation and constriction of pupils, and influences the fluid dynamics within the eye that are vital in managing intraocular pressure and optic nerve health. Glaucoma is a disease that damages the eye’s optic nerve and usually happens when fluid builds up and increases pressure inside the eye. The Kiritsu-Meijin device measures autonomic function by assessing the body’s response to posture changes, and can provide important information on the sympathetic and parasympathetic activities during these transitions. To this end, new study published in the Journal of Current Eye Research and Led by Professor Toru Nakazawa from the Tohoku University and conducted by Yurina Yamada, Naoki Kiyota, Mitsuhide Yoshida, and Kazuko Omodaka, the researchers investigated the relationship between autonomic dysfunction, as measured by the Kiritsu-Meijin device, and visual field defects in patients with open-angle glaucoma (OAG).¹ In their study, the team enrolled patients diagnosed with open-angle glaucoma at Tohoku University Hospital who were previously diagnosed based on characteristic optic nerve damage and corresponding visual field defects without elevated intraocular pressure (IOP). The researchers used the Kiritsu-Meijin Device, which measures autonomic function and records heart rate variability during specific posture changes. The test they performed included sitting for two minutes to record baseline autonomic activity, standing for two minutes to assess the sympathetic nervous response, and sitting again for one minute to measure parasympathetic recovery. They measured basal activity, balance between autonomic systems, reaction to standing, switchover to sympathetic response, and recovery. Additionally, they performed visual field testing with the Humphrey Field Analyzer to obtain detailed analysis of mean and total deviations across various sectors of the visual field.

The authors found significant positive correlations between the parameters of activity, balance, and recovery, and the mean deviation values from visual field testing. This implies that lower scores in these autonomic parameters are associated with more severe visual field defects. Moreover, they showed that the severity of visual field defects varied across different sectors of the visual field. Notably, autonomic dysfunction (particularly lower activity and recovery scores) was more strongly associated with defects in the central and inferior visual field sectors compared to the superior sector. According to the authors, assessment of autonomic function with the Kiritsu-Meijin device, could serve as a useful clinical tool in the management of glaucoma. Additionally, the correlation between autonomic dysfunction and visual field severity may help in stratifying patients according to the risk of progression and tailoring treatment strategies accordingly. Indeed, the same research team previously shown that older patients with low blood flow had inferior visual field damage in glaucoma.²

Overall, Professor Toru Nakazawa’s and his research team study contribute to better understanding of the pathophysiology and management of OAG by examining autonomic function. It also highlighted that glaucoma’s risk factors extend beyond IOP to include ANS dysfunction, which suggests that vascular and neurogenic factors also play critical roles in the disease’s progression. The study’s proposal to measure autonomic parameters with the Kiritsu-Meijin device supported the potential for early detection and intervention, possibly before traditional indicators such as IOP changes become clear. This could lead to personalized treatment approaches targeting autonomic balance through pharmacological or lifestyle interventions. Additionally, the study offers insights into the uneven impact of autonomic dysfunction on different visual field sectors, which could refine diagnostic and monitoring practices and change the current glaucoma treatment paradigm  and enhance patient outcomes.

Mild traumatic brain injury (mTBI) is a significant public health concern due to its high prevalence and potential for long-term cognitive adverse effects. Conventional neuroimaging techniques like computed tomography (CT) often fail to detect abnormalities in mTBI patients especially in those presenting with negative CT scans. The lack of detectable injury on imaging with persistent symptoms is still a challenge in accurate diagnosis and best management for mTBI. It is believed the pathophysiology of mTBI is complex and involves neuronal injury, neuroinflammation, and vascular dysfunction which also play a significant role in the long-term progression and potential neurodegeneration associated with mTBI. Previous studies suggested that blood-based biomarkers could provide valuable data into these underlying molecular mechanisms. Biomarkers such as neurofilament light (NfL), ubiquitin C-terminal hydrolase L1 (UCH-L1), and vascular endothelial growth factor (VEGF) have shown promise in reflecting axonal damage, neuronal cell body injury, and vascular changes, respectively. However, the temporal dynamics of these biomarkers and their precise relationship with neuroimaging findings and clinical outcomes in CT-negative mTBI patients remain unclear. To this account, new study published in Journal of Cerebral Cortex and conducted by PhD candidate Xiaoyan Jia, Xuan Li, Qiuyu Ji, Bo Yin, Yizhen Pan, Wenpu Zhao, Ming Zhang, Guanghui Bai, Jie Zhang, and led by Professor Lijun Bai from Xi’an Jiaotong University, the researchers performed comprehensive longitudinal study to investigate the potential of serum biomarkers in diagnosing and monitoring CT-negative mTBI. They focused on a cohort of mTBI patients with negative CT scans to elucidate the temporal profiles of key biomarkers and their association with neuroimaging abnormalities and cognitive function which enhanced our understanding of mTBI’s pathophysiology and provided guidelines for improved clinical management and therapeutic interventions.

To investigate the diagnostic and prognostic potential of serum biomarkers, the researchers measured levels of neurofilament light (NfL), UCH-L1, and VEGF, along with inflammatory cytokines (IL-1β, IL-6, IL-10). Blood samples were processed using a Luminex multiplex bead system and Simoa technology for NfL quantification. They observed NfL to be elevated in acute-stage mTBI patients compared to HCs which indicated axonal injury. These elevated NfL levels were associated with impaired white matter integrity and progressive brain atrophy which highlighted NfL’s potential as a marker for neurodegeneration. Another biomarker UCH-L1 which was also found to be elevated at both the acute and 3-month stages which reflects neuronal cell body injury and its levels correlated with cognitive flexibility impairment and highlighted the impact of neuronal injury on cognitive functions. Moreover, VEGF displayed the highest diagnostic potential with an AUC of 0.88 and was significantly elevated in acute-stage patients and also associated with post-traumatic symptoms which suggested its role in angiogenesis and brain recovery processes.

In their study, participants also underwent diffusion tensor imaging (DTI) and high-resolution T1-weighted MRI scans. DTI metrics, such as fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD), were analyzed to assess white matter integrity. The authors also evaluated brain volume changes using the Jacobian determinant (JD) metric to identify progressive atrophy. The authors found that acute mTBI patients have increased MD and RD in the corpus callosum which suggest cellular inflammation and potential demyelination while there were no significant differences found in chronic mTBI patients compared to HCs which indicated a resolution of some microstructural changes over time. They also showed using JD analysis progressive atrophy in both gray and white matter regions from the acute stage to 6-12 months post-injury with atrophy to be more significant in the frontal and temporal lobes which emphasizes the longitudinal impact of mTBI on brain structure. The research team assessed cognitive flexibility using the Digital Symbol Coding score from the Wechsler Adult Intelligence Scale III and found impairment was associated with elevated IL-1β and UCH-L1 levels from the acute to chronic stages highlighting the role of acute inflammatory responses and neuronal injury in long-term cognitive outcomes. Sleep disturbance was also evaluated using the Insomnia Severity Index. Post-concussive symptoms were assessed based on ICD-10 criteria and demonstrated it can be predicted by elevated VEGF levels at the acute stage which indicate the potential impact of angiogenesis-related processes on post-injury sleep quality.

In conclusion, the study by Professor Lijun Bai and her colleagues identified VEGF as a highly effective diagnostic biomarker for distinguishing CT-negative mTBI patients from healthy controls which demonstrates the potential for improved early diagnosis and this could lead to better management and treatment strategies for patients who might otherwise be overlooked due to negative CT scans. The findings and analysis that successfully linked specific biomarkers to neuronal injury, neuroinflammation, and vascular dysfunction advances our knowledge of mTBI’s complex pathophysiology which can be critical for developing better treatments. According to the authors measuring serum biomarkers such as NfL, UCH-L1, and VEGF in routine clinical practice can provide non-invasive and accessible method for diagnosing and monitoring mTBI and offer objective measures to complement traditional diagnostic tools. Moreover, the authors’ findings of biomarkers to be associated with specific pathological processes and outcomes allows for more personalized treatment strategies. For example, patients who have elevated inflammatory biomarkers might benefit from anti-inflammatory medications while those with high NfL levels could receive medications that axonal integrity. Finally, the authors recommended regular monitoring of biomarker levels because it could help clinicians track better disease progression and treatment efficacy over time which ultimately led to improved patient outcomes.

Acknowledgement

We  acknowledge Prof. Jie Zhang from the Department of Radiation Medicine, School of Preventive Medicine, Air Force Medical University, and Prof. Ming Zhang from the Department of Medical Imaging, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China, for their great contributions to this research work.

There has been significant interest in the development of messenger RNA (mRNA)-based treatments lately which are uniquely is able to directly instruct cells to produce specific proteins which makes mRNA an attractive candidate for personalized medicine because it allows for tailored therapies that can be adjusted in dosage and frequency to meet individual patient needs. Despite these advantages, the clinical application of mRNA therapies still faces significant challenges. One of the primary hurdles is the inherent instability of mRNA molecules, because they are sensitive to rapid degradation by ribonucleases (RNases) present in extracellular fluids and biological environments. Another critical challenge is the efficient delivery of mRNA into the cells because naked mRNA molecules are too large and negatively charged, which make them unable to internalize. Moreover, even when mRNA enters the cells through endocytosis, it often remains trapped within endosomes, where it can be degraded before reaching the cytoplasm. For the effective mRNA therapies drug development, they must overcome these limitations. Although various delivery systems have been proposed to address these issues such as lipid-based and polymer-based carriers which showed promise in protecting mRNA from degradation and facilitating its cellular uptake. However, these systems often encounter limitations in terms of stability, efficiency of endosomal escape, and potential cytotoxicity. To this end, Professor Hyun-Ouk Kim at Kangwon National University and conducted by HakSeon Kim, Yu-Rim Ahn, Minse Kim, Jaewon Choi, SoJin Shin developed a novel mRNA delivery system termed “ChargeSomes which improved the stability and delivery efficiency of mRNA through the use of charge-complementary polymersomes. The new study is now published in the Pharmaceutics Journal.

The first step the researchers synthesized the charge-complementary polymers methoxy polyethylene glycol-block-poly-L-lysine (mPEG-b-PLL) and methoxy polyethylene glycol-block-poly-L-lysine-succinic anhydride (mPEG-b-PLL-SA) and then confirmed the successful synthesis of these copolymers using nuclear magnetic resonance and Fourier-transform infrared spectroscopy. The physicochemical properties of ChargeSomes were then analyzed using dynamic light scattering and transmission electron microscopy which demonstrated that ChargeSomes formed stable, spherical nanoparticles with a bilayer structure. These nanoparticles varied in size depending on the ratio of mPEG-b-PLL to mPEG-b-PLL-SA, with a 9:1 ratio showing optimal characteristics for mRNA delivery. Afterward, the authors assessed the stability of ChargeSomes, and they monitored the size distribution in phosphate-buffered saline at pH 7.4 over six weeks using DLS and they showed that ChargeSomes maintained consistent stability at neutral pH, indicating their robustness under physiological conditions. Furthermore, to evaluate the pH sensitivity, ChargeSomes were exposed to an acidic environment, simulating endosomal conditions. The nanoparticles exhibited significant size changes between 3 and 8 hours, confirming their pH-responsive behavior and capacity to release mRNA in acidic environments, essential for effective endosomal escape. The team also evaluated the cytotoxicity of ChargeSomes using RAW 264.7 cells and showed that ChargeSomes has minimal cytotoxicity across various concentrations and ratios of mPEG-b-PLL to mPEG-b-PLL-SA. Specifically, a 7:3 ratio showed high cell viability, confirming the safety of ChargeSomes for therapeutic applications. According to the authors, at a concentration of 0.21 mM, ChargeSomes exhibited optimal characteristics for further in vitro experiments, maintaining cell viability comparable to that of lipofectamine, a commonly used transfection reagent. Moreover, the researchers examined the efficiency of cellular uptake and endosomal escape of ChargeSomes using confocal laser-scanning microscopy (CLSM) and flow cytometry. Ovalbumin conjugated with fluorescein isothiocyanate (FITC–OVA) served as a model antigen to track cell uptake. The author’s findings indicated that OVA–FITC-encapsulated ChargeSomes showed superior cellular uptake compared to OVA–FITC alone, as evidenced by increased green fluorescence intensity in RAW 264.7 cells. Flow cytometry further corroborated these findings, with higher fluorescence levels in cells treated with ChargeSomes. To analyze endosomal escape, the authors incubated the cells with ChargeSomes over a temporal gradient and their studies demonstrated rapid transition from cell uptake to endosomal escape within 6 hours highlights the efficiency of ChargeSomes in delivering mRNA.

The researchers further tested the transfection efficiency of ChargeSomes using Enhanced Green Fluorescent Protein (EGFP) mRNA and confirmed the encapsulation and stability of EGFP mRNA within ChargeSomes, even in the presence of PBS, RNase, and fetal bovine serum. In contrast, cells treated with naked mRNA exhibited no EGFP expression, suggesting degradation or failed internalization of unencapsulated mRNA. Quantitative evaluation using flow cytometry revealed that mRNA delivery via ChargeSomes significantly improved EGFP expression efficiency compared to naked mRNA. The results indicated that ChargeSomes facilitated effective endosomal escape and cytoplasmic delivery of mRNA, with the 9:1 ratio showing the highest transfection efficiency due to its optimal physicochemical properties.

One of the major contributions of the new study is the development of a delivery system that significantly enhances the stability and protection of mRNA molecules. ChargeSomes shield mRNA from degradation by RNases and the use of charge-complementary polymers ensures that the mRNA is securely encapsulated, which is a substantial improvement over traditional delivery methods that often fail to provide adequate protection. In conclusion, Professor Hyun-Ouk Kim and his team demonstrated that ChargeSomes is a safe and efficient mRNA delivery technology that can enhance cellular uptake and promote effective endosomal escape. Additionally, the practical implications of work of Professor Hyun-Ouk Kim and colleagues extend to the development of non-viral gene therapy as well as mRNA vaccines.  Future studies should further confirm the in vivo efficacy of ChargeSomes in animal models and eventually in human trials. The versatility of the ChargeSome platform allows for the potential development of delivery systems for other types of nucleic acids, such as small interfering RNA (siRNA) or DNA which will broaden the scope of gene therapy applications.

Circulating tumor DNA (ctDNA) refers to fragments of DNA that are released from cancer cells into the bloodstream. These DNA fragments are shed into the blood either through the apoptosis (programmed cell death) or necrosis (cell death due to injury) of tumor cells. The fragments of ctDNA are usually short, often around 160-180 base pairs. This is in contrast to circulating free DNA (cfDNA) from healthy cells, which is typically longer. The presence of ctDNA in the blood offers a unique opportunity for non-invasive cancer diagnosis and monitoring, a method often referred to as a “liquid biopsy.”  The amount of ctDNA in the blood can vary widely among patients and depends on factors such as the type and stage of cancer, the tumor burden, and the effectiveness of treatments.

Since ctDNA carries the genetic signature of the tumor, analyzing ctDNA can help in the early detection of cancer, potentially even before clinical symptoms appear. Moreover, changes in the levels of ctDNA can indicate how well a patient is responding to treatment. A decrease in ctDNA levels might suggest that the treatment is effective, while an increase could indicate progression or recurrence of the disease. Furthermore, analysis of ctDNA can help identify specific mutations within the tumor. This information can be critical for selecting targeted therapies that are more likely to be effective against cancers with certain genetic profiles. However, detecting ctDNA can be challenging, especially in early-stage cancers where the quantity of ctDNA is very low. Improvements in technology and methods are continually being made to enhance the sensitivity of ctDNA detection. As research advances, the potential applications of ctDNA in personalized medicine are expanding. This includes not only cancer detection and monitoring but also the possibility of using ctDNA profiles to guide therapy choices and predict patient outcomes. However, further studies and clinical trials are needed to fully integrate ctDNA analysis into standard oncology practice. The development of more sensitive and specific ctDNA assays will also be key in realizing the full potential of this technology in cancer care.

Liquid biopsy, a rapidly advancing technology, has revolutionized the approach to cancer diagnostics. Traditionally, tissue biopsies have been the gold standard for tumor analysis. However, they are invasive, often painful, and sometimes impossible if the tumor location is unknown or inaccessible. This limitation has driven the development of liquid biopsies, which use a simple blood draw to detect ctDNA.   The core issue with liquid biopsies is the scarcity of circulating tumor DNA in blood, which is often too limited for effective detection, especially in early-stage cancers or small tumors. Martin-Alonso et al. tackled this challenge by introducing two types of priming agents that transiently attenuate the natural clearance of cfDNA in blood. This approach resulted in a significant increase in the recovery of ctDNA from blood draws, thereby enhancing the sensitivity of liquid biopsies.

In a new study published in Science Journal and led by Dr. Viktor Adalsteinsson from the Gerstner Center for Cancer Diagnostics at Broad Institute of MIT and Harvard,  researchers focused on enhancing the sensitivity and reliability of liquid biopsies for tumor detection. Liquid biopsies, which involve analyzing cfDNA in blood samples, offer a non-invasive method to detect ctDNA. However, the inherent challenge with this approach has been the low abundance of ctDNA in blood, particularly in cases of early-stage cancers or small tumors. To address this challenge, the researchers developed two distinct types of priming agents that temporarily inhibit the natural clearance of cfDNA from the bloodstream. This strategy aimed to increase the concentration and therefore the detectability of ctDNA in a standard blood draw. Here’s an overview of their approach:

The first priming agent is based on nanoparticles that target the cells responsible for cfDNA clearance, primarily the liver-resident macrophages. The research demonstrated that these nanoparticles, by saturating the uptake capacity of these macrophages, significantly prolonged the half-life of cfDNA in circulation. The second type of agent involved DNA-binding monoclonal antibodies (mAbs). These mAbs bind to cfDNA, shielding it from enzymatic digestion, and thus prolonging its presence in the bloodstream. The effectiveness of these agents was validated in mouse models of cancer. The results were striking – a more than tenfold increase in ctDNA recovery, enabling more accurate tumor molecular profiling from blood samples. Notably, the sensitivity for detecting small tumors increased dramatically from under 10% to over 75%. This finding is particularly significant as early detection is crucial for effective cancer treatment. The implications of this study for clinical practice are profound. Priming agents could revolutionize liquid biopsies, making them a more reliable tool for early cancer detection, monitoring disease progression, and tailoring personalized treatment strategies. This advance could also extend the utility of liquid biopsies to other applications, such as prenatal testing, infectious diseases, and organ transplant monitoring. While the study presents promising results, several challenges must be addressed before these priming agents can be used clinically. First, the safety and efficacy of these agents need to be established in human trials. The interaction of these agents with human physiology, potential side effects, and long-term implications must be thoroughly investigated. Moreover, the integration of these priming agents into existing clinical workflows will require careful consideration. For instance, the timing of blood draws relative to the administration of priming agents will be crucial to maximize ctDNA recovery. Additionally, the cost-effectiveness of incorporating these agents into routine clinical practice must be evaluated. In conclusion, the study led by Dr. Adalsteinsson marks a significant advancement in the field of liquid biopsies. By enhancing the sensitivity and robustness of ctDNA testing, these novel priming agents hold the promise of transforming cancer diagnostics and management. As with any groundbreaking technology, rigorous clinical testing and thoughtful integration into healthcare systems are essential to realize their full potential. The future of cancer diagnostics looks brighter with such innovations paving the way for more accurate, non-invasive, and patient-friendly testing methods.

Soft tissue sarcomas (STSs) are a rare group of cancers originating from the connective tissue stroma, constituting approximately 1% of all cancer cases. Among them, primary mediastinal sarcomas are even rarer, accounting for 10% of primary mediastinal tumors and only 1% of all STSs. Due to their rarity and the heterogeneity in disease progression, STSs have been less frequently studied in the past, with limited data available primarily from small retrospective case series. The median overall survival for STS patients has historically been disappointing, with a reported average of 27.2 months. Undifferentiated pleomorphic sarcoma (UPS), a high-grade sarcoma with no specific differentiation direction, lacks distinctive clinical manifestations or immunohistochemical markers, making histopathological examination the gold standard for diagnosis. Vimentin positivity can enhance diagnostic specificity. For patients with advanced sarcoma, the prognosis remains dismal, and doxorubicin monotherapy has been the standard first-line chemotherapy option. However, the outcomes have been unsatisfactory, underscoring the urgent need for more effective therapies. In recent years, immunotherapy with immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) pathway has shown promising results in various cancer types. Monoclonal antibodies blocking PD-1 and PD-L1 interaction can activate T lymphocytes, preventing immune evasion by tumors. The presence of tumor-infiltrating lymphocytes and PD-L1 expression in tumor and immune cells has been associated with treatment response. However, evidence on the efficacy of ICIs in UPS has been limited to small-sample studies, such as the phase II SARC028 trial, which indicated some efficacy of ICIs in UPS treatment but did not result in official approval for sarcoma treatment.

In a new study published in the Frontiers in Oncology Journal by Dr. Hujuan Yang, Dr. Zhiquan Qin, Dr. Xianglei He, Dr. Qian Xue, Dr. Hongying Zhou, Dr. Jie Sun, Dr. Xiaoyi Li and Dr. Tongwei Zhao from the Zhejiang Provincial People’s Hospital discussed a clinical case report of a patient with primary UPS characterized by high PD-L1 expression who responded well to immunotherapy, highlighting the potential of ICIs in the treatment of this rare and aggressive cancer.

The patient in question was a 61-year-old man who presented with chest pain. Imaging studies revealed a potentially malignant cardiac mass and abnormal lymph nodes in the neck region, suggestive of metastasis. Subsequent pathological analysis confirmed the presence of a malignant tumor with lymph node involvement. Further immunohistochemical staining showed that the tumor exhibited characteristics consistent with UPS, and PD-L1 expression was notably high (tumor proportion score [TPS] = 80%). According to the American Joint Committee on Cancer (AJCC) 8th edition staging, the patient was classified as cT3N1M1 (stage IV) due to tumor invasion of the pericardium, rendering surgical resection unfeasible. Consequently, the patient received a combination of epirubicin and tislelizumab chemotherapy for six cycles, which resulted in a partial response (PR) with a progression-free survival (PFS) of 8.5 months. However, during treatment, the patient experienced cardiotoxicity attributed to epirubicin, leading to its discontinuation in favor of tislelizumab monotherapy for maintenance. Subsequent imaging demonstrated stable disease, but later scans revealed disease progression with new lesions, ultimately leading to the patient’s demise from obstructive jaundice caused by tumor progression.

The new study showed that immunotherapy, specifically immune checkpoint blockade, has shown promise in the treatment of STS. Notably, UPS has been identified as a tumor type with a relatively higher incidence of PD-L1 expression. Several ongoing clinical trials are evaluating the safety and efficacy of ICIs in various STS subtypes. In the presented case, the patient exhibited high PD-L1 expression and tumor-infiltrating lymphocytes, indicative of a potential response to immunotherapy. The combination of tislelizumab and epirubicin resulted in a PR and an extended PFS, surpassing the average survival duration reported for conventional chemotherapy in UPS.

The clinical case presented by Dr. Tongwei Zhao and colleagues highlights the potential of immunotherapy, particularly immune checkpoint inhibitors, in the treatment of primary mediastinal UPS with high PD-L1 expression. While UPS is a rare and aggressive cancer, patients with high PD-L1 expression and tumor-infiltrating lymphocytes may benefit from immunotherapy. This case report provides a valuable addition to the growing body of evidence supporting the use of immunotherapy in the management of STS. However, further research, including larger clinical trials and mechanistic studies, is required to fully understand and optimize the role of immunotherapy in UPS treatment.

The recent advancements in synthetic biology have opened up new avenues in medical diagnostics, particularly in cancer detection. A groundbreaking development in this field is the engineering of bacteria to detect specific DNA sequences and mutations associated with tumors. This innovative approach leverages the natural ability of bacteria to take up DNA from their environment, combined with sophisticated genetic engineering, to create living biosensors capable of identifying tumor DNA. The implications of this technology are vast, offering a potential paradigm shift in early cancer detection and monitoring.

Traditional methods of cancer detection, such as imaging and biopsy, often detect cancer at later stages when treatment options are limited. Molecular diagnostics have improved early detection, but these methods can be invasive, expensive, and require complex laboratory infrastructure. The emerging field of synthetic biology offers a promising alternative. By engineering living cells to respond to specific molecular signals, researchers can create biosensors that detect disease markers directly in the body.  Engineered bacteria designed to detect cancer represent a significant advancement in the field of biotechnology and medical diagnostics. These genetically modified microorganisms are tailored to recognize specific biomarkers associated with various types of cancer.

In a new study published in the Journal Science led by University of California, San Diego scientists, they engineered bacteria for tumor DNA detection and undertook an innovative approach to cancer diagnostics. They genetically modified naturally competent bacteria, such as Acinetobacter baylyi, enabling them to detect specific DNA sequences associated with tumors. The researchers chose bacteria capable of horizontal gene transfer (HGT), specifically Acinetobacter baylyi. They used CRISPR-Cas systems to modify these bacteria. The CRISPR system was programmed to recognize and integrate specific DNA sequences found in tumor DNA. The focus was on oncogenic mutations, like those in the KRAS gene, which are prevalent in various cancers such as colorectal cancer (CRC).

The authors designed the engineered bacteria to detect specific oncogenic mutations, such as those in the KRAS gene, a common marker in various cancers including colorectal cancer (CRC). These bacteria carry CRISPR-Cas systems programmed to recognize and integrate only the mutated DNA sequences. When these bacteria come into contact with tumor DNA, either in vitro or in a living organism, they incorporate the DNA containing the cancer-specific mutation. This incorporation leads to a change in the bacterial phenotype, such as resistance to a particular antibiotic, which can be easily detected. The bacteria’s ability to detect specific mutations suggests they could identify cancer at a much earlier stage compared to traditional methods. The authors highlighted the possibility of introducing these bacteria into the human body in a non-invasive manner, like oral administration, for continuous monitoring of tumor DNA.

The new biosensing approach offers several advantages over traditional cancer detection methods, first, it can be non-Invasiveness where the bacteria can be introduced into the body non-invasively, through oral administration or rectal enema. Secondly, the bacteria can continuously monitor the gut environment, providing real-time data on the presence of tumor DNA. The new method can potentially detect cancer at a much earlier stage than traditional methods, as it can identify specific DNA mutations associated with early cancer development. Being a living system, these biosensors could be more cost-effective to produce and deploy compared to complex molecular diagnostics. While promising, the clinical application of engineered bacteria as biosensors raises several important considerations: the safety of introducing genetically modified organisms into the human body must be thoroughly evaluated. Moreover, the accuracy of these biosensors in differentiating between benign and malignant cells, and their sensitivity in detecting low levels of tumor DNA, need extensive validation.

Looking ahead, the potential of engineered bacteria in cancer detection is immense. This technology could revolutionize how we diagnose and monitor cancer, making early detection more accessible and less invasive. Additionally, it opens the door for the development of similar biosensors for a wide range of diseases, beyond cancer. The integration of synthetic biology with medical diagnostics promises a new era of precision medicine, where treatments can be tailored and monitored at the molecular level in real time. In conclusion, the use of engineered bacteria as living biosensors for tumor DNA detection represents a significant leap forward in cancer diagnostics. This innovative approach harnesses the power of synthetic biology to offer a more sensitive, non-invasive, and potentially cost-effective method for early cancer detection. As research progresses, these bacteria could become part of personalized medicine approaches, providing early and accurate diagnosis for various types of cancer. They might also be engineered to deliver therapeutic agents directly to tumor sites, acting as a dual diagnostic and therapeutic tool.

Parkinson’s disease (PD) is characterized as a progressive neurodegenerative disorder with symptoms including tremor, rigidity, and bradykinesia. The disease’s etiology is multifactorial, involving both environmental and genetic factors. Within the genetic domain, mutations in the LRRK2 gene represent significant risk factors, given their role in regulating and interacting with RAB GTPases, which are critical for cellular trafficking and signaling. A new international collaborative study published in the Journal Lancet Neurology and led by Professor Matthew Farrer from the University of Florida, the researchers focused on the genetic underpinnings of Parkinson’s disease, specifically through the lens of RAB GTPase variability in familial cases. This extensive study not only highlights a novel genetic variant associated with the disease but also underscores the complex genetic landscape that underpins Parkinson’s pathogenesis. The primary aim of this study was to investigate the genetic variability within the RAB GTPases among familial Parkinson’s disease cases, particularly where no genetic cause had been previously identified. The research hypothesized that mutations in RAB GTPases could be linked to Parkinson’s, providing new insights into the disease mechanisms and potential therapeutic targets. First, the authors used whole-exome sequencing on probands from families with Parkinson’s disease in Canada and Tunisia. These families were selected based on their unknown genetic etiology and familial disease occurrence. The researchers screened 61 RAB GTPases, identifying candidate variants which were further tested in affected family members through linkage analysis and in broader case-control cohorts via genotyping. Validation of findings involved bioinformatic analyses using multiple databases including AMP-PD, GP2, and the 100,000 Genomes Project, among others.

The team identified 15 RAB GTPase variants, with a particular focus on the RAB32 variant c.213C>G (Ser71Arg), which showed significant cosegregation with disease in multiple families. This variant was associated with an early onset of Parkinson’s disease and demonstrated a significant effect size in meta-analyses across several databases. Functional assays indicated that the Ser71Arg mutation enhances LRRK2 kinase activity, suggesting a direct mechanistic link to Parkinson’s pathology. Interestingly, this variant was observed across diverse ethnic groups, indicating its widespread relevance. The discovery of the RAB32 Ser71Arg mutation represents a significant advancement in understanding the genetic basis of Parkinson’s disease. It suggests a novel mechanism through which LRRK2-related pathways may be disrupted and highlights the importance of RAB GTPases in the disease’s pathogenesis. The findings advocate for the inclusion of RAB32 in genetic screening for Parkinson’s, especially in familial cases with unknown genetic causes.

The identification of the RAB32 Ser71Arg variant as a novel genetic risk factor for Parkinson’s disease is a primary significance of this study. This discovery adds to the known spectrum of genetic variations that contribute to the pathogenesis of Parkinson’s, providing insights into the molecular mechanisms underlying the disease. Moreover, the study highlights the role of RAB GTPases, particularly RAB32, in the regulatory pathways involving LRRK2, a protein previously implicated in Parkinson’s. By demonstrating that the RAB32 Ser71Arg variant enhances LRRK2 kinase activity, the research provides a new perspective on how alterations in cellular trafficking and signaling pathways could contribute to neurodegeneration.  Since the variant was predominantly studied in familial cases of Parkinson’s disease, the findings have significant implications for genetic counseling and testing in these populations. Families with a history of Parkinson’s can benefit from targeted genetic screening, potentially leading to earlier diagnosis and personalized management strategies. Furthermore, understanding the interaction between RAB32 and LRRK2 opens up potential therapeutic avenues. If RAB32 influences LRRK2 activity, modulating this interaction might offer a new therapeutic strategy, particularly for patients who carry this or similar mutations. Additionally, the detection of the RAB32 Ser71Arg variant across multiple ethnicities enhances the global relevance of the findings. This diversity underscores the importance of including varied populations in genetic studies, which can lead to more universally applicable Parkinson’s disease treatments and strategies. This study lays the groundwork for further research into other RAB GTPases and their potential roles in Parkinson’s disease. The findings encourage deeper exploration of the genetic architecture of Parkinson’s and highlight the need for comprehensive studies involving larger cohorts and diverse populations to validate and expand upon these results.

The study’s implications extend beyond mere genetic curiosity, suggesting potential new targets for therapeutic intervention and highlighting the importance of genetic counseling in families with prevalent Parkinson’s disease. Future research should focus on further delineating the role of RAB32 and other GTPases in Parkinson’s, exploring their interactions with other proteins, and validating these findings in larger, more diverse populations. Moreover, the study opens up avenues for investigating the therapeutic potential of modulating LRRK2 and RAB32 interactions. Overall, the study significantly enriches our understanding of the genetic landscape of Parkinson’s disease, with implications for diagnostics, treatment, and our understanding of the disease’s pathophysiology. The comprehensive genetic analysis has not only identified a novel genetic variant associated with familial Parkinson’s disease but also underscored the complexity of genetic factors contributing to the disease. The findings enrich our understanding of the genetic architecture of Parkinson’s disease and provide a foundation for future research and therapeutic development.

Epigenetic clocks use changes in DNA methylation patterns across the genome to build predictive models that can estimate biological age, age-related diseases, assess the effects of environmental factors on aging, and evaluate the efficacy of anti-aging interventions. Because the global population are increasingly aging, neurodegenerative diseases are affecting more individuals, and therefore there is an urgent need to develop improved methods for early diagnosis, and to understand better mechanism of disease progression, and develop new treatment strategies. To this end, a new study published in the Journal of Neurology, Neurosurgery and Psychiatry, led by Professor Huifang Shang from the Department of Neurology at West China Hospital, Sichuan University, offers a comprehensive systemic review on the application of epigenetic clocks in neurodegenerative diseases. Conducted by Dr. Tianmi Yang, Yi Xiao, Yangfan Cheng, Jingxuan Huang, Qianqian Wei, and Chunyu Li, the research critically evaluates risk factors, age of onset, diagnosis, progression, prognosis, and pathology in Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). The authors identified studies that used epigenetic clocks with keywords related to ageing and DNA methylation. Afterward, they extracted the relevant data from the selected studies on study design, sample size, type of epigenetic clock used, biological tissues analyzed, main findings, and methodological approaches. They also assessed quality and risk of bias of the included studies to ensure the reliability and validity of the findings of their work. The approach they conducted aligned with the preferred reporting items for systematic reviews and meta-analyses guidelines. Their inclusion criteria focused on studies that reported data on the use of epigenetic clocks, which are biological markers that aim to provide a measure of an individual’s biological age based on DNA methylation patterns. These clocks calculate the methylation age of tissues and compare it to chronological age to determine age acceleration or deceleration. The authors successfully collected information from 23 studies that they used to reliably review the role of epigenetic clocks in neurodegenerative diseases.

With regard to AD, the authors said the epigenetic clocks revealed significant associations between accelerated DNA methylation age and common risk factors of AD, such as BMI and smoking. Some of the reported studies suggested that DNA methylation age could assist in predicting the age of onset and diagnosing AD through correlations with biomarkers like amyloid-beta and tau protein levels. Moreover, the progression of AD was also linked to changes in DNA methylation age, although findings were mixed across different studies and epigenetic clocks. On the other hand, studies showed that PD patients often had an accelerated DNA methylation age compared to controls. This acceleration was associated with earlier disease onset and more rapid progression of both motor and cognitive symptoms.  Another neurodegenerative disease they investigated was ALS and they showed DNA methylation age acceleration was linked to earlier disease onset. It also correlated with worse prognosis and higher risk of death, indicating its potential use as a prognostic marker in ALS. However, they reported limited data of DNA methylation age acceleration and progression in HD especially in relation to motor symptom severity.

Overall, the study by Professor Huifang Shang and her colleagues is significant because it enhanced our understanding of how accelerated biological aging correlates with the development and progression of neurodegenerative diseases. Moreover, their important epigenetic clocks in serving as valuable biomarkers for earlier and more accurate diagnosis of neurodegenerative diseases essential for effective treatment planning and patient care management. Furthermore, the establishment of a link between epigenetic age acceleration with neurodegenerative diseases, the authors open possibilities for new therapeutic interventions targeting the underlying aging processes that contribute to disease onset and progression. For instance, future research that identifies changes in DNA methylation age and its correlation with disease progression, researchers can identify new therapeutic targets that might slow or reverse epigenetic aging, and hence impact disease onset and progression. They also advocated to integrate epigenetic clocks into individual biological aging studies, which potentially will allow for more personalized medical interventions in neurology based on a person’s biological rather than chronological age.  Lastly, the expert opinion review of Professor Shang and team identified important knowledge gaps and called for the need for further longitudinal research to better use of epigenetic clocks, that can lead to the development of disease-specific, tissue-specific, or phenotype-specific clocks that better inform the molecular mechanisms of neurodegeneration.

Non-small cell lung cancer (NSCLC) represents the most common type of lung cancer, accounting for about 85% of all lung cancer cases. NSCLC comprises several subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each differing in their cellular makeup and behavior. Treatment for NSCLC varies based on the stage of the disease, the patient’s overall health, and specific characteristics of the cancer, such as genetic mutations or biomarkers. In recent years, immunotherapy has emerged as a significant advancement in the treatment of various cancers, including NSCLC. Immunotherapy leverages the body’s immune system to recognize and fight cancer cells more effectively. Durvalumab is a monoclonal antibody that plays an important role in this therapeutic approach, particularly for NSCLC. Durvalumab targets Programmed Death-Ligand 1 (PD-L1), which is expressed on the surface of many cancer cells, including some NSCLC cells. PD-L1 binds to the PD-1 receptor on T-cells, effectively “turning off” these cells and preventing them from attacking the cancer. By binding to PD-L1, durvalumab blocks its interaction with PD-1, thereby reactivating the T-cells and enabling them to recognize and destroy cancer cells. The effectiveness of durvalumab in treating NSCLC has been demonstrated in several clinical trials. It has been particularly beneficial in patients with locally advanced, unresectable NSCLC that has not progressed after standard platinum-based chemotherapy and radiation therapy. In such cases, durvalumab has been shown to improve progression-free survival and, in some studies, overall survival rates compared to standard care. However, there is a significant fraction of patients either do not respond to such treatments or develop resistance over time. The resistance mechanisms are multifactorial, involving alterations in DNA damage response and repair pathways, mutations in key tumor suppressor genes like STK11/LKB1, dysregulation in antigen-presentation pathways, and the presence of immunosuppressive cellular subsets within the tumor microenvironment.

A recent study published in Nature Medicine under the leadership of Professor John Heymach from MD Anderson Cancer Center reported the HUDSON phase 2 umbrella study, which evaluated the efficacy of combining durvalumab  with various agents such as ceralasertib (ATR kinase inhibitor), olaparib (PARP inhibitor), danvatirsen (STAT3 antisense oligonucleotide), and oleclumab (anti-CD73 monoclonal antibody) in patients who have previously experienced failure in treatments involving anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy.

The HUDSON study was carefully designed to address these challenges by exploring combination regimens that target potential resistance mechanisms. The choice of combination therapies—durvalumab with either ceralasertib, olaparib, danvatirsen, or oleclumab—is informed by a deep understanding of the underlying biology of NSCLC and resistance to immunotherapy. For instance, the combination of durvalumab and ceralasertib is particularly noteworthy. Ceralasertib, an ATR kinase inhibitor, is posited to synergize with durvalumab by targeting DNA damage response pathways, thereby enhancing the immunogenicity of cancer cells and improving the efficacy of immunotherapy.

The authors showed that the combination of durvalumab and ceralasertib demonstrated the most significant clinical benefit among the tested regimens. This combination yielded an objective response rate of 13.9%, a median progression-free survival of 5.8 months, and a median overall survival of 17.4 months. These outcomes are particularly remarkable considering the refractory nature of the patient population under study. The data also suggest that patients with ATM alterations, hypothesized to be more vulnerable to ATR inhibition, benefit significantly from the durvalumab-ceralasertib regimen.

A critical aspect of the HUDSON study is its emphasis on biomarker analyses to tailor treatments to individual patients’ molecular profiles. This approach aligns with the principles of personalized medicine, aiming to maximize therapeutic efficacy while minimizing unnecessary exposure to potentially ineffective treatments. The authors’ findings highlight the importance of comprehensive genomic profiling in guiding treatment decisions and highlight the potential of combining targeted therapies with immunotherapy to overcome resistance mechanisms. It is important to mention that the authors evaluated the safety and tolerability profile of the combination regimens, especially durvalumab and ceralasertib, which was manageable, paving the way for further investigation possibly phase 3 clinical trials. Indeed, the HUDSON study not only contributes valuable insights into the mechanisms of resistance to immunotherapy in NSCLC but also sets a precedent for the design of future clinical trials that seek to integrate targeted therapies with immunotherapy in a biomarker-driven manner.

In conclusion, the HUDSON study represents a significant milestone in the ongoing quest to improve outcomes for patients with NSCLC, particularly those with tumors lacking targetable alterations and who have exhausted standard-of-care options. The study’s innovative design, rigorous biomarker analyses, and promising clinical outcomes provide a robust foundation for future research aimed at refining and expanding therapeutic options for this challenging patient population. The combination of durvalumab and ceralasertib, in particular, emerges as a promising therapeutic strategy warranting further exploration in the quest to enhance the efficacy of immunotherapy in NSCLC.